Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy

Trial Identifier: MEQ00086
Sponsor: Sanofi Pasteur, a Sanofi Company
Start Date: September 2023
Primary Completion Date: September 2024
Study Completion Date: September 2024
Condition: Meningococcal Immunisation; Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
ARGENTINA, Ciudad de Buenos Aires Buenos Aires, Ciudad de Buenos Aires, ARGENTINA, 1430
ARGENTINA, Not Known Ciudad Autonoma Buenos Aires, Not Known, ARGENTINA, C1425EFD